Stockscreener 앱 받기
4.8616
1.22%
-0.0684
전일 마감가:
$4.93
열려 있는:
$4.94
하루 거래량:
24,267
Relative Volume:
0.08
시가총액:
$182.67M
수익:
$147.12M
순이익/손실:
$-33.88M
주가수익비율:
-4.5765
EPS:
-1.0623
순현금흐름:
$2.63M
1주 성능:
+11.19%
1개월 성능:
-2.99%
6개월 성능:
-37.80%
1년 성능:
-27.53%
1일 변동 폭
$4.81
$4.94
1주일 범위
$4.39
$5.15
52주 변동 폭
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
명칭
Lifecore Biomedical Inc
전화
(952) 368-4300
주소
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.87 | 184.92M | 147.12M | -33.88M | 2.63M | -1.0623 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.265 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.72 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.67 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.66 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | 개시 | William Blair | Outperform |
| 2024-09-05 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
모두보기
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
LFCR Q1 2026 Earnings: Wider Loss Than Expected Despite Positive Stock ReactionGlobal Trading Community - Newser
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference - Sahm
LFCR Stock Price, Quote & Chart | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore CEO, CFO to meet investors at June 2-4 Chicago conference - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 Earnings Miss by Significant: Key TakeawaysCollaborative Trading Signals - Newser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift - MSN
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029 - MSN
Lifecore Biomedical to Participate at CDMO Live Europe - The Manila Times
TradingKey - TradingKey
The sustainable advantages Lifecore Biomedical (LFCR) is developing (+0.42%) 2026-05-10Fast Rising Stocks - newser.com
Number of shareholders of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN
LFCR Lifecore Biomedical shares slide 3.83% as Q1 2026 earnings miss estimates by 75.7% despite modest revenue growth.Social Momentum Signals - newser.com
The steady strength in Lifecore Biomedical (LFCR) story (Softens) 2026-05-08Company Analysis - newser.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript - Sahm
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Maintains Target Price $6 - Moomoo
MSN Money - MSN
Lifecore Biomedical: Q1 Earnings Snapshot - theheraldreview.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-05-06 - Seeking Alpha
Lifecore Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Keybanc Initiates Coverage of Lifecore Biomedical (LFCR) with Sector Weight Recommendation - MSN
Lifecore Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifecore Biomedical Q1 Earnings Call Highlights - Yahoo Finance
LFCR: Revenue fell 34% in Q1 2026, but cost controls and new programs support reaffirmed 2026 guidance - TradingView
Lifecore Biomedical 1Q 2026: Revenue $23.19M, EPS ($0.43) — 10-Q Summary - TradingView
Lifecore (NASDAQ: LFCR) posts 34% revenue drop and high debt load - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 revenue drops but 2026 outlook reaffirmed - Stock Titan
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update - The Manila Times
Lifecore Biomedical Q1 revenue falls 34%, misses analyst estimates - TradingView
Lifecore lands 3 new transfer programs while cutting operating costs - Stock Titan
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026 - The Manila Times
Before the bell May 6, Lifecore releases Q1 results, holds 8 a.m. webcast - Stock Titan
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR) - Insider Monkey
[DEF 14A] LIFECORE BIOMEDICAL, INC. DE Definitive Proxy Statement - Stock Titan
Lifecore Biomedical Inc (LFCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.89%
자본화:
|
볼륨(24시간):